Your browser doesn't support javascript.
loading
Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial.
Hou, Zhiguo; Lan, Chunyan; Huang, Xin; Salcedo-Hernández, Rosa A; El-Tawab, Sally.
Affiliation
  • Hou Z; Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
  • Lan C; Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Huang X; Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Salcedo-Hernández RA; Gynecological Cancers Division, Instituto Nacional de Cancerología de México (Mexico's National Cancer Institute), Mexico City, Mexico.
  • El-Tawab S; Oxford Gynaecological Cancer Centre, Churchill Hospital, Oxford University Hospitals Foundation Trust, Oxford, UK.
Transl Cancer Res ; 12(10): 2959-2967, 2023 Oct 31.
Article in En | MEDLINE | ID: mdl-37969395
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Cancer Res Year: 2023 Document type: Article Affiliation country: China Country of publication: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Cancer Res Year: 2023 Document type: Article Affiliation country: China Country of publication: China